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Alcohol use disorders are common in developed countries, where alcohol is cheap, readily available, 
and heavily promoted. Common, mild disorders often remit in young adulthood, but more severe 
disorders can become chronic and need long-term medical and psychological management. Doctors 
are uniquely placed to opportunistically assess and manage alcohol use disorders, but in practice 
diagnosis and treatment are often delayed. Brief behavioural intervention is eﬀective in primary care 
for hazardous drinkers and individuals with mild disorders. Brief interventions could also encourage 
early entry to treatment for people with more-severe illness who are underdiagnosed and 
undertreated. Sustained abstinence is the optimum outcome for severe disorder. The stigma that 
discourages treatment seeking needs to be reduced, and pragmatic approaches adopted for patients 
who initially reject abstinence as a goal. To engage people in one or more psychological and 
pharmacological treatments of equivalent eﬀectiveness is more important than to advocate a 
speciﬁc treatment. A key research priority is to improve the diagnosis and treatment of most 
aﬀected people who have comorbid mental and other drug use disorders. 
 
Introduction 
Alcohol use disorders are among the most common and undertreated mental disorders in developed 
countries.1 Aﬀected individuals have impaired control over their alcohol consumption and continue 
to drink despite the serious adverse eﬀects on their health and the lives of their spouses, children, 
family members, friends, and workmates. 
Applying Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5)2 diagnostic 
criteria, in 2012–13 36·0% of male and 22·7% of female adults in the USA met the criteria for alcohol 
use disorders at some time in their lives, and 17·6% of men and 10·4% of women did so in the past 
year.3 Diﬀerences between the sexes have narrowed because women’s drinking patterns have 
become similar to men’s in recent birth cohorts.4 The risk of development of an alcohol use disorder 
increases with the frequency of binge drinking, although most heavy drinkers do not meet the 
criteria for alcohol dependence.5 
The disorders are most prevalent in young adulthood (age 18–29 years).3 Mild disorders often remit 
as young adults enter the labour market, marry, and assume responsibility for children.6 More-
severe alcohol use disorders are one of the most undertreated mental disorders, with less than 15% 
of patients receiving treatment.7 The ﬁrst episode of treatment is delayed until the disorder is well 
established, typically after age 30 years.8 Doctors are uniquely placed to opportunistically assess and 
manage alcohol use disorders. In this Seminar, we describe eﬀective behavioural and 
pharmacological treatments and emerging research directions. 
 
Alcohol-related burden of disease 
Alcohol consumption is causally linked to 60 diﬀerent diseases. The major causes of premature 
death to which it contributes are injury, alcoholic liver disease, heart disease and stroke, cancers, 
and gastrointestinal disease.9 Cardiovascular beneﬁts might be gained from very low levels of 
alcohol use for middle-aged men (typically age 40–60 years), but these beneﬁts are most likely to be 
seen in developed countries where risk of heart disease is high. Even in these countries, the total 
harm caused by alcohol use in the population far outweighs the modest cardiovascular beneﬁts.10 
Alcohol use contributes to around 4% of the global burden of disease. This contribution is equivalent 
to that of tobacco smoking because alcohol use causes more premature deaths in young adults than 
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does tobacco smoking.11 This burden is greatest in developed countries, where more people 
regularly drink to intoxication and other causes of mortality are low.11 The harms caused by alcohol 
are related to the average volume of alcohol consumed and the pattern of drinking. The risk of harm 
rises steeply when more than 10–20 g of alcohol is consumed per day. Episodic drinking to 
intoxication greatly increases the risks of accidents, injuries, violence, and heart disease.11 
People with alcohol use disorders account for around half of all the alcohol-related harm in 
developed societies.12 The remainder arises from accidents, assaults, and suicides in young adults, 
especially men, who engage in episodic drinking to intoxication, but most of whom do not meet the 
criteria for alcohol use disorders. The harms arising from both intoxication and such disorders need 
to be prevented to reduce the burden of alcohol- related harm.5 
 
Diagnostic systems 
Version 10 of the International Classiﬁcation of Diseases13 distinguishes “harmful use” from 
“dependence”, whereas DSM-III14 to DSM-IV-TR15 (1980–2013) distinguished between “alcohol 
abuse” and “alcohol dependence”. These two categories have been combined in DSM-52 into one 
category—“alcohol use disorder”—because of empirical evidence that symptoms of such disorders 
vary in severity along one dimension (appendix).16 
According to DSM-5, at least two of 11 symptoms need to be present for diagnosis of an alcohol use 
disorder. Severity is assessed by the number of symptoms recognised (appendix). 
 
Behavioural and neurobiological eﬀects 
Alcohol aﬀects a wide range of neurotransmitter systems in the brain that are implicated in 
cognition, emotion, and motivation.17 At low doses, alcohol has rewarding, anxiolytic, and socially 
facilitating eﬀects. As the dose increases, alcohol produces cognitive and psychomotor impairment 
that increases the risks of injury, and it also disrupts emotional regulation in ways that contribute to 
assaults. 
The pleasurable eﬀects of alcohol provide an explanation for the initiation and persistence of alcohol 
use and a part explanation for the development of alcohol use disorders. The repeated pairing of 
environmental cues and rewards enhances alcohol’s subjective and physiological eﬀects via 
conditioning18 and social and cognitive learning about the eﬀects of alcohol (ie, alcohol 
expectancies). Outcome expectancies (eg, tension reduction and increased conﬁdence) and 
individuals’ beliefs about their ability to refrain from drinking (ie, self-eﬃcacy) contribute to the risk 
of development of alcohol use disorders.19 Individuals with high alcohol expectancies and low self-
eﬃcacy are at increased risk of problem drinking.19 Both factors can be modiﬁed by cognitive 
behaviour therapies (table 1).28 
Alcohol crosses the blood–brain barrier and interacts with many neurotransmitter systems rather 
than a single molecular target. It increases GABA, glycine, nicotinic acetylcholine, and serotonin 
activity. It also indirectly increases dopamine, opioid, and endocannabinoid activity (ﬁgure) and 
inhibits glutamate transmission. These complex eﬀects contribute to acute intoxication. The 
pleasurable eﬀects seem to be mediated by increased dopaminergic transmission in the mesolimbic 
reward system. 
2 
 
Author postprint of Connor, J. P., Haber, P. S., & Hall, W. D. (2016). Seminar: Alcohol use 
disorders. Lancet, 387(10022), 988–998. doi:10.1016/s0140-6736(15)00122-1.  
Please refer to publication version for tables, figures and boxes mentioned in the text. 
 
The clinical features of alcohol dependence include tolerance and withdrawal. With repeated dosing, 
neurotransmitter responses are reduced, and increased doses of alcohol are needed to produce the 
same eﬀect. Abrupt cessation produces rebound eﬀects that are experienced as withdrawal 
symptoms. Each of the neurotransmitter systems aﬀected by alcohol has been targeted with some 
success by pharmacological treatments. An increased understanding of the neurobiology holds 
promise to translate into improved targeted drug treatments for alcohol dependence. 
 
Risk factors for alcohol use disorders 
Patients and their families need to understand that alcohol use disorders are not merely a result of 
an individual moral failing but arise from the combined eﬀects of many personal, social, and 
biological factors. The prevalence of alcohol use disorders in the population is increased in cultures 
that encourage adults to drink to intoxication. These cultures typically make alcohol readily available 
at low cost, allow use in everyday settings, and create a social milieu in which drinking to 
intoxication is socially approved and promoted by ubiquitous alcohol advertisements.31 Early 
initiation and hazardous alcohol consumption in adolescence predict a raised risk of development of 
alcohol use disorders in adulthood.32 Other risk factors include a family history of alcohol 
dependence, low parental monitoring and poor family support, childhood conduct and mood 
disorders, low self-control and impulsivity, and positive alcohol expectancies.33 Peer alcohol use is 
one of the strongest predictors of adolescent alcohol use.33 People with a family history of early-
onset alcohol use disorders in several male and female ﬁrst-degree relatives are at high risk of 
development of such disorders.34 This pattern shows the combined eﬀects of increased genetic risk 
and a childhood environment in which parents model heavy drinking. 
Twin studies estimated that 50–70% of the risk of alcohol use disorders is attributable to additive 
genetic factors.35 The strongest genetic association is with a genotype that reduces the risk. Alcohol 
dehydrogenase and the mitochondrial form of aldehyde dehydrogenase (ALDH2) are liver enzymes 
that metabolise alcohol. The ALDH2 genotype is expressed by two primary alleles known as ALDH2*1 
and ALDH2*2. Carriers of ALDH2*2 (ie, those with a single copy of the allele) have impaired alcohol 
metabolism. If they drink alcohol, they usually have facial ﬂushing, sweating, tachycardia, nausea, 
vomiting, and headache, which protect against development of alcohol use disorders.36 This 
polymorphism is carried by roughly 23% of all Asian populations (range 1–53%) but is rare in 
Europeans.36 
Risk alleles have been identiﬁed that modestly increase the risk of alcohol use disorders.37 These 
alleles aﬀect neurotransmitter responses to alcohol in the dopaminergic, opioidergic, GABAergic, 
serotonergic, cholinergic, and glutamatergic systems. These gene variations each contribute less 
than 1% of the genetic risk for alcohol use disorders.38 The hope is that the remaining contributors to 
genetic risk will be identiﬁed39 by higher- powered genome-wide association studies that examine 
the diﬀerences between cases and controls across large numbers of single-nucleotide 
polymorphisms. 
 
Clinical presentation, signs, and symptoms in primary care 
Drinkers often underestimate their alcohol consumption 40 because standard drink units are usually 
poorly understood and vary between 8 g in the UK and 19·75 g in Japan.41 Recommended low-risk 
alcohol consumption values also vary between countries, but typical ranges are 20–40 g per day 
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(<200 g per week) for men and 10–30 g per day (<140 g per week) for women. With the variations in 
glass size and average pours, these values roughly equate to two to three drinks (eg, glasses of wine, 
shots of whisky) per day for men and one to two drinks per day for women. These values 
approximate Rehm and colleagues’42 estimated lifetime risk thresholds for alcohol-related mortality 
from chronic illness (two drinks per day) and acute injury (three to four drinks per day). Medical and 
other health professionals should be familiar with national safe drinking guidelines and the alcohol 
content of widely consumed beverages. Age of onset and duration of alcohol use, pattern of use, 
and circumstances of any periods of abstinence should be assessed. 
Roughly half of individuals with alcohol use disorders remain undiagnosed if doctors rely only on 
their clinical judgment.43 Structured questions about alcohol use and brief questionnaires such as 
CAGE,44 the Michigan Alcohol Screening Test,45 and Alcohol Use Disorders Identiﬁcation Test 
(AUDIT)46 can identify patients who need further assessment. The ten-item WHO AUDIT46 is useful in 
detection of problem drinking in a range of clinically and culturally diverse populations (sensitivity 
and speciﬁcity typically 80–90%).47,48 It takes less than 2 min to complete and is easily scored. Scores 
of 8 or higher suggest hazardous drinking, and scores of 16 or higher suggest probable alcohol 
dependence. A brief version of the AUDIT (AUDIT C), consisting of the ﬁrst three questions (how 
often is alcohol consumed, how many alcoholic drinks are typically drunk in a day, and how often are 
six or more drinks consumed), has similar psychometric properties to the full scale. A cutoﬀ score of 
3 has been suggested for hazardous drinking and 4 for possible alcohol use disorder.47 
 
Management 
Patients are most likely to be diagnosed and managed in a medical setting—eg, when they are 
treated in hospital for an alcohol-related injury, or gastrointestinal or liver disease. The adverse 
eﬀects of their alcohol use might be discovered in the course of other treatment—eg, preparation 
for surgery or via abnormal blood tests. A patient seeking treatment for an alcohol use disorder is 
less common. 
Clinical assessment should obtain a detailed history of alcohol use, the symptoms of alcohol use 
disorder (panel), and the details of the last drinking session. The use of other substances, including 
tobacco and prescription drugs, should be assessed. Patients should be asked about any harm to 
their physical and mental health, social situation, including interpersonal and forensic issues, and 
their work. Their insight into the contribution of alcohol to their health problem and their motivation 
to change their drinking habits should be assessed. Inquiries should be made about any previous 
treatment for alcohol use disorders, its outcome, and any mental health symptoms, diagnoses, or 
treatment. 
Physical examination should begin by assessment of symptoms of intoxication and withdrawal. 
Intoxication manifests in slurred speech, ataxia, and inappropriate aﬀect. Alcohol value should be 
measured in the blood or breath. The earliest signs of withdrawal are restlessness, tachycardia, and 
a ﬁne action tremor. 
A neurological examination should look for signs of Wernicke’s encephalopathy or acute intracranial 
lesion. The classic triad of confusion, ataxia, and nystagmus suggests Wernickes’ encephalopathy, 
but most cases will have only one or two signs.49,50 Tests should be done for upper motor neuron 
signs, particularly lateralising signs, such as pupillary asymmetry, that suggest an intracranial lesion. 
Orientation, short-term memory, mental state, insight, and motivation should be assessed, as should 
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common cerebellar signs such as nystagmus and ataxia. A general medical examination should 
identify other physical signs of alcohol use disorders (panel) and exclude unrelated disorders. In 
particular, alcohol is an under- recognised leading reversible cause of hypertension.51,52 
 
Diagnostic investigations 
Standard blood tests, including liver tests and mean corpuscular volume of red blood cells (MCV), 
are often abnormal in people with alcohol use disorders, but these tests have low sensitivity and 
speciﬁcity.53,54 γ-glutamyl transpeptidase (gGT) is the most widely used marker but is of little value 
because of poor sensitivity and speciﬁcity (table 2): gGT can detect only about one in ﬁve cases of 
heavy drinking.53 Its predictive value is greatest in overweight (body-mass index [BMI] >25 kg/m²) 
men older than 40 years.55–57 It is rarely helpful in detection of heavy drinking in young lean women 
(age <20 years).58 The most common cause of high gGT is an increased BMI.55 Other causes of liver 
disease and some drugs reduce the speciﬁcity of gGT as a marker of alcohol use disorders. Uric acid, 
triglycerides, MCV, and liver enzymes are commonly raised but are not speciﬁc to alcohol use 
disorders. The presence of several abnormalities is uncommon but suggestive of alcohol use 
disorders. 
Biomarkers for alcohol use that are more sensitive and speciﬁc than standard clinical assays exist, 
but they are not widely used because of their high cost and limited availability. These biomarkers 
include carbohydrate- deﬁcient transferrin, ethyl glucuronide, ethyl sulphate, phosphatidyl ethanol, 
and fatty acid ethyl esters (table 2).54  
Once a disorder is recognised, full blood count and biochemical, glucose, and liver tests are 
important in assessment of medical complications. Alcohol use disorders are associated with 
nutritional disorders, but vitamin testing is costly and not routinely recommended. Imaging studies 
(eg, in the brain and liver) should be done only when clinically indicated. 
 
Acute management 
A heavy drinker who cannot be roused should be admitted to hospital to prevent fatal aspiration. 
Airway protection, hydration, management of seizures, and monitoring of blood glucose and 
ketoacidosis might be necessary. Individuals with alcohol intoxication who show aggressive 
behaviour might need intramuscular sedation in the emergency department.59 Supportive care 
protects unconscious patients from injury. Patients should be monitored for withdrawal as 
intoxication resolves. 
Withdrawal can be managed in the community, primary care, specialist services, or hospital, 
according to its severity and the availability of services. The most widely used withdrawal 
assessment scale is the clinical institute withdrawal assessment for alcohol (revised version; CIWA-
Ar).60 It is sensitive, reproducible, and can be used with minimum training, but a high score can show 
intercurrent illnesses rather than alcohol withdrawal. No withdrawal scale has been validated in the 
inpatient setting, in which comorbidity is prevalent. Rating scores should be checked carefully before 
treatment is modiﬁed. Serious comorbidity is probably better managed without use of a scale. 
The most widely used drugs for management of alcohol withdrawal are benzodiazepines.61 These 
drugs can be given by ﬁxed (eg, day 1: 20 mg four times; day 2: 10 mg four times; day 3: 10 mg 
twice; day 4: 5 mg twice; day 5: 5 mg up to twice if needed; day 6: cease), symptom- triggered, or 
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front-loading regimens. High doses are generally needed in the ﬁrst 24 h. They are then tapered over 
the next few days and cease within 5–7 days of initial treatment. Symptom-triggered dosing needs 
monitoring of withdrawal severity according to the CIWA-Ar, dose adjustment when needed, and 
close nursing care. Fixed dosing is most practical in less well monitored settings, including home 
detoxiﬁcation. 
Inpatients with comorbidities could be most safely managed by ﬁxed dosing with daily clinical 
review. Front loading via hourly dosing of 10–20 mg diazepam is appropriate for those with severe 
withdrawal symptoms. It is ceased once the patient settles. Risks of benzodiazepines include 
oversedation and benzodiazepine dependence. In jaundiced patients with liver failure, oxazepam is 
preferred to diazepam because it has a short half-life and no active metabolites.61 Sedation is 
hazardous in patients with head injury or respiratory failure, and should be done only with specialist 
oversight in high-dependency units. 
Potentially fatal complications of alcohol withdrawal include seizures and delirium. Withdrawal 
delirium (ie, delirium tremens) occurs in roughly 5% of patients. Few controlled trials to direct 
management or dosing regimens have been done.60 Delirium is probably best managed with 
intravenous benzodiazepines and antipsychotic drugs in an inpatient or intensive-care unit setting. 
Other agents trialled to treat withdrawal include baclofen, gabapentin, carbamazepine, and valproic 
acid. The few studies of these drugs have had mixed ﬁndings. Until better evidence is obtained, 
these drugs should not be used in routine clinical practice.61 
Many patients do not need sedation; they do well with reassurance in a safe, alcohol-free 
environment. Supportive care should monitor and manage dehydration, electrolyte disorders, and 
infections, and monitor complications. The risk of relapse to alcohol use after withdrawal exceeds 
90%, so further treatment is needed to reduce this risk.62 
Wernicke-Korsakoﬀ syndrome is a devastating neurological complication of alcohol use disorders 
that can produce lifelong disability or death. Symptoms such as confusion, ataxia, or nystagmus 
often emerge during alcohol withdrawal. The evidence base to guide treatment of the syndrome is 
poor,63 and no randomised controlled trials have been done in the past decade. Guidelines64,65 are 
related to clinical experience, pathophysiology where known, and the ease of thiamine 
supplementation. 
Prophylactic parenteral thiamine should be given in every case. The ﬁrst parenteral dose of thiamine 
should be given in the emergency department without delay. Present practice is to give thiamine 
before any dextrose, although a recent review66 reported little evidence that intravenous dextrose 
precipitates the syndrome. For prophylaxis, a parenteral dose of 200 mg per day is recommended. 
For treatment of suspected or established Wernicke-Korsakoﬀ syndrome, the recommended dose is 
500 mg given intravenously three times per day for 2–3 days.49 Further treatment is guided by 
response. Oral thiamine treatment should be continued until sustained abstinence is achieved, and 
indeﬁnitely if the person continues to drink. 
 
Diﬀerential diagnosis 
In epidemiological surveys, half of all individuals with a lifetime history of alcohol use disorders have 
at least one other mental health disorder.67 Treatment studies typically exclude patients with 
concurrent psychiatric diagnoses, making it diﬃcult to advise how to manage the most common 
forms of comorbidity, such as anxiety and mood (so-called internalising) disorders.68 A 
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comprehensive psychiatric assessment is essential to identify the primary disorder or disorders 
(psychiatric or alcohol use disorder) for treatment planning. Engagement of patients in treatment is 
crucial, and motivational strategies might assist (table 1).69,70 Mood symptoms typically reduce with 
abstinence,71,72 but treatment might be needed for mood and anxiety disorders that do not remit.73 
Research into how to best manage patients with comorbid alcohol use disorders and other mental 
disorders,74,75 or drug and alcohol use disorders, is scarce.69,76–80 A research priority is to do high-
quality treatment trials of patients with alcohol use disorders who have the most common forms of 
psychiatric comorbidity. 
Most individuals also have another substance use disorder. At least half are tobacco smokers81 and a 
third have another drug use disorder.67 Alcohol and tobacco potentiate the risk for head and neck 
cancers.82 People using more than one substance have poorer mental health than do those using 
only one substance.83 Alcohol and benzodiazepine use is often overlooked.84 Patients who also use 
more than one substance have poor outcomes from behavioural treatment.25 
Heavy drinkers who are prescribed CNS depressants and opioids need to be carefully monitored.85,86 
Dependence on both alcohol and opioid is dangerous. Most fatal and non-fatal opioid overdoses 
occur in combination with use of alcohol or benzodiazepine, or both,87 often as a result of 
respiratory depression.85,88 Whether detoxiﬁcation is needed for individuals with dependence on 
other substances needs to be established; if so, evidence-based approaches should be used.89 
Alcoholic liver disease is the most common serious medical complication of alcohol use disorders. 
Almost 50% of the worldwide burden of liver disease has been attributed to alcohol consumption.90 
The risk of alcoholic liver disease is highest in overweight (BMI >25–30 kg/m²) and obese (BMI >30 
kg/m²) individuals, in women, and in those with a family history of alcoholic liver disease, hereditary 
haemochromatosis, and chronic viral hepatitis B and C. Patients presenting with alcoholic liver 
disease usually have less severe alcohol use disorder91 and have consumed less alcohol than those 
without such disease.57 
Alcoholic liver disease is recognised by clinical hepatomegaly or abnormal ultrasound. The liver tests 
are abnormal and, in most cases, have dominant gGT concentrations and higher concentrations of 
aspartic acid aminotransferase than alanine aminotransferase. Treatment options are few. 
Abstinence is essential in all but trivial cases of alcoholic liver disease and improves survival.92 Few 
treatment trials have been done for people presenting with alcoholic liver disease, but one trial has 
shown baclofen to be safe and eﬀective.93 
 
Brief behavioural interventions 
Brief interventions are recommended for all patients who are drinking hazardously. They usually last 
5–20 min and typically include one to three sessions.94,95 They provide information and advice on 
safe levels of consumption and might include motivational inter- viewing (table 1).96 More frequent, 
brief interventions are usually more eﬀective than one extended session.94,95 Brief interventions are 
moderately eﬀective and can reduce problem drinking in primary-care patients94 and inpatients;95 
more-intensive interventions in emergency departments97 and sexual health services can also do 
so.98 Studies have been predominantly done in middle-aged male drinkers. Variations in the content 
and intensity of brief interventions create uncertainty over how they work,99 and more research is 
needed to assess their beneﬁts. 
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Screening and brief interventions could encourage people with alcohol use disorders to receive 
treatment early. Patients scoring 0–7 in the AUDIT in primary care100 should be given basic alcohol 
education, those scoring 8–15 given straightforward advice on reduction of hazardous drinking, 
those scoring 16–19 given straightforward advice in addition to brief counselling and continued 
monitoring, and those scoring 20–40 referred for specialist assessment. 
 
Relapse prevention 
Follow-up studies of untreated patients show average abstinence of 21% for up to 1 year.101 Most 
patients reduce their frequency of heavy drinking because of illness, adverse social eﬀects, or the 
urging of family members.102 After formal treatment, meta-analyses ﬁnd abstinence ranging from 
25%103 to 43%,104 dependent on treatment intensity and length of follow-up. 
Behavioural treatments improve outcomes (table 1).20,104 These approaches diﬀer in rationale but 
seem to be similarly eﬀective.20,21,105 In practice, diﬀerent behavioural approaches are often 
combined. Motivational inter- viewing is most widely used to engage patients in treatment so that 
cognitive and behavioural approaches can modify dysfunctional cognitions and address skill 
deﬁcits.106 Treatment can take place on an individual or a group basis. Engagement of spouses of 
people with alcohol use disorders in joint therapy is eﬀective.107 12-step facilitation is the most 
widely recognised group intervention.106 
Diﬀerent pharmacotherapies for relapse prevention are similarly eﬀective.108 Three drugs have been 
approved by the equivalent of the US Food and Drug Administration (eg, Therapeutic Goods 
Administration in Australia) to treat alcohol use disorders by maintenance of abstinence: naltrexone, 
acamprosate, and disulﬁram (table 3). Naltrexone and acamprosate have similar eﬃcacy (number 
needed to treat 9–12).109 Meta-analyses show that acamprosate is probably more eﬀective in 
maintenance of abstinence,109–111 whereas naltrexone is best at prevention of heavy drinking.109,110 
The combination of acamprosate and naltrexone resulted in fewer relapses than did single agents in 
some studies115,116 but not in the largest study done so far.117 No robust data for optimum length 
of pharmacotherapy exist because the average duration of treatment trials is 6 months for 
acamprosate and 3 months for naltrexone.109 
Two recent meta-analyses 113,114 found disulﬁram eﬀective only when dosing was supervised, and 
little evidence of longer-term eﬀectiveness exists.109 Disulﬁram might be suitable only for highly 
motivated, supervised patients who will also do well with other pharmacotherapies that have fewer 
adverse eﬀects and contraindications. 
Nalmefene has been approved by the European Medicines Agency to reduce alcohol use rather than 
achieve abstinence (table 3). It is taken when the patient feels at risk of drinking.118 In one large 
multisite outpatient trial, nalmefene signiﬁcantly reduced heavy drinking days and daily 
consumption in patients who continued to drink.119 Its use has a clinical and public health 
justiﬁcation. It helps heavy drinkers to reduce their average consumption. It is also a cost-eﬀective 
way to reduce the population burden of alcohol-related disease.120 The available evidence does not 
provide clear recommendations about which drug or psychosocial intervention is best for which 
patients. Therefore, best practice is for physicians to encourage their patients to choose from 
available treatments that have proved safe and eﬀective. 
Alcoholics Anonymous is a widely used intervention for alcohol use disorders. Evidence for its 
eﬀectiveness is mixed (table 1). Many patients ﬁnd the social support provided by 12-step self-help 
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groups useful in maintenance of abstinence, especially if they have no other social support. Those 
who have chosen abstinence as a goal should be encouraged to attend these meetings. The SMART 
recovery model is an alternative self-help approach for individuals who reject the religious aspects of 
the 12-step approach. 
Alcohol use disorders are highly stigmatised,121,122 and many people with them do not seek 
treatment for this reason.7 Less stigmatising attitudes could be encouraged by a diagnostic approach 
that emphasises a continuum of symptoms rather than a dichotomous diagnostic category.123 If so, 
the adoption of a severity continuum in DSM-5 could increase treatment engagement. 
A crucial aspect is to engage patients in any evidence- based treatment.124 The similar eﬀectiveness 
of behavioural 21,105 and pharmacological approaches suggests that patients should be given a choice 
of clinically indicated treatments. 109 Patient-centred care and shared decision making also help to 
destigmatise alcohol use disorders and engage patients in treatment. 124 
Another important aspect is to increase patients’ motivation to address their drinking habits, resolve 
their ambivalence about alcohol use, set realistic goals, and engage in decision making.125 Patients 
with more-severe disorders (eg, high levels of dependence, high craving, end-organ damage, and 
severe social disruption) should be encouraged to add drug treatment to their existing treatment.124 
Further ﬁeld testing will examine whether the DSM-5 severity index (appendix) could guide health 
professionals and patients in their choice of the type and intensity of treatment. 
Sustained abstinence is the optimum outcome for most patients with an alcohol use disorder. Risk of 
relapse reduces considerably after 10–14 weeks of abstinence.126 Abstinence is recommended for 
those with more-severe alcohol use disorders, end-organ damage, and severe social disruption. The 
treatment goal will aﬀect pharmacotherapy choice. Meta-analyses 109–112 suggest that acamprosate 
and disulﬁram might be better suited to abstinence-oriented treatment, whereas naltrexone and 
nalmefene might be better choices when reduced or controlled drinking is the goal. 
Few patients with severe alcohol use disorders can return to moderate drinking, 6,103 but many 
initially reject abstinence as a goal, which is often a barrier to their engagement in treatment. 127 A 
pragmatic approach is to clinically engage with patients who insist on controlled or reduced-risk 
drinking as the goal of treatment. This approach enables a therapeutic relationship to develop and 
leaves open the future modiﬁcation of treatment goal—eg, the failure to achieve control over 
drinking could suggest the need for abstinence.128 
Patients who are unresponsive to treatment in primary care and as outpatients might need 
structured residential treatment in a therapeutic community or rehabilitation programme. These 
patients usually have more-severe alcohol use disorders, little social support for abstinence, and 
unstable living conditions. In populations with drug and alcohol abuse, little evidence exists that 
diﬀerent types of residential services have diﬀerent outcomes.129 Cost and unavailability of facilities 
might restrict use of this option. Online treatment and telephone-based helplines130 have recently 
been trialled to increase treatment access for problem drinkers who are reluctant to seek traditional 
treatment. These treatments vary in content and delivery. Randomised controlled trials of internet-
based treatment in college populations show large variations in response rates and retention.130,131 
In alcohol-dependent populations, little evidence is currently available for telephone-based 
interventions130 or internet-based interventions.131 This rapidly developing area of research could, in 
future, deliver more eﬀective online treatments for alcohol use disorders. 
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Public health policies are a cost-eﬀective way to reduce the substantial population health burden 
that is attributable to alcohol intoxication—eg, policies that make alcohol more expensive by 
increase in taxation, and less accessible by restrictions on the sale and promotion of 
alcohol.10,33,132,133 These policies are also eﬀective in reduction of the prevalence of alcohol use 
disorders.31 
 
Unresolved research questions 
Preclinical and early clinical studies have investigated new drugs to treat alcohol use disorders. 
These drugs include selective antagonists (and agonists) of opioid, cannabinoid, nicotinic, 
neuropeptide, and dopaminergic receptors, and agents that modulate glutamate activity, glycine 
activity, the hypothalamic–pituitary–adrenal axis, and γ-aminobutyric-acid systems.134,135 On the 
basis of our review, drugs that have shown more consistent results but have not yet been approved 
for use include topiramate, gabapentin, baclofen, and varenicline (appendix). 
Genetic factors could determine the eﬀects of drugs and guide treatment selection, but the data are 
not suﬃciently robust to justify routine clinical use of genetic tests. The Asn40Asp polymorphism of 
the opioid receptor, mu 1 (OPRM1) gene has been linked to eﬀectiveness of naltrexone treatment in 
some but not all studies.136 The rs2832407 polymorphism in the GRIK1 gene, which encodes the 
kainate glutamate receptor subunit, could aﬀect the eﬀectiveness of topiramate treatment.137 High-
quality replications are needed. 
Research into health services is needed to better identify and treat the most common and 
remediable forms of psychiatric comorbidity in patients with alcohol use disorders—namely, anxiety 
and mood disorders. We need much better evidence to decide when treatment is needed for these 
psychiatric comorbidities and how best to integrate such treatment into the treatment of alcohol 
use disorders. 
 
Conclusions 
Alcohol use disorders contribute substantially to the burden of disease in many developed countries. 
Mild forms often remit without treatment, but the more severe forms are underdiagnosed and 
undertreated. The diagnosis and treatment of more-severe illness need to be improved—eg, doctors 
could screen patients in high-risk settings, reduce stigma, and engage patients earlier in eﬀective 
psychological and pharmacological treatments. Ideally, patients should be oﬀered a choice of 
behavioural or pharmacological treatments, or a combination of both. A pragmatic approach should 
be adopted towards patients who initially reject abstinence as a treatment goal. 
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